Strategies to Mitigate the Toxicity of Cancer Therapeutics

Erscheinungsjahr 2022
ISBN: 978-0-323-90087-4
Verlag: William Andrew Publishing

Buch, Englisch, 256 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 570 g

Strategies to Mitigate the Toxicity of Cancer Therapeutics, Volume 155 in the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting interesting chapters, each of which is written by an international board of authors.

Zielgruppe

<p>Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.</p>

Autoren/Hrsg.

Weitere Mitwirkende

Gewirtz, David A.

Fachgebiete

• Naturwissenschaften Biowissenschaften Zellbiologie
• Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
• Naturwissenschaften Biowissenschaften Virologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie

Inhaltsverzeichnis

Contributors in this volume include:

Annemieke Kavelaars
Nitesh Kumar
Imad Damaj
Ningjun Li
Maryam Lustberg
Hamid Akbarali
Fadi Salloum

Über Autor(innen)

Gewirtz, David A.
Dr. Gewirtz received his PhD degree from Mt. Sinai School of Medicine of the City University of New York. He has been at Virginia Commonwealth University in the Department of Pharmacology and Toxicology and as a member of the Massey Cancer Center for his entire career. His work has been in the areas of cancer chemotherapy and radiotherapy, originally in breast cancer, but more recently extending to lung cancer, prostate cancer and head and neck cancer. His interests have long been in the nature of alternative tumor responses to therapy, most prominently autophagy and senescence. He has long argued that senescence is not an irreversible form of growth arrest, that senescence could represent one form of tumor dormancy and furthermore that recovery from senescence could contribute to disease recurrence. His most recent publication describes the impact of the senolytic agent, ABT-263 (navitoclax) on breast and lung tumor cells induced into senescence by cancer chemotherapy and radiation.